Analysis Article • May 01
Have your own idea? Try our Stock Screener
Swedish (OMX) Clinical Research and Equipment Industry Analysis
UpdatedMay 30, 2026
DataAggregated Company Financials
Companies9
- 7D-3.6%
- 3M-0.6%
- 1Y-16.3%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 3.4%, driven by MedCap declining 9.8%. Meanwhile, Promimic actually outperformed within the industry, gaining 29% in the last week. Overall the industry is down 17% in 12 months. Earnings are forecast to grow by 20% annually.
Industry Valuation and Performance
Has the Swedish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 30 May 2026 | SEK 29.0b | SEK 14.6b | -SEK 849,175,077.00 | 34x | -34.1x | 2x |
| Mon, 27 Apr 2026 | SEK 29.8b | SEK 14.6b | -SEK 970,997,077.00 | 34.5x | -30.7x | 2x |
| Wed, 25 Mar 2026 | SEK 26.1b | SEK 14.6b | -SEK 838,374,077.00 | 31.6x | -31.1x | 1.8x |
| Fri, 20 Feb 2026 | SEK 27.4b | SEK 14.6b | -SEK 878,801,427.00 | 32.7x | -31.2x | 1.9x |
| Sun, 18 Jan 2026 | SEK 30.0b | SEK 14.9b | -SEK 744,515,427.00 | 47x | -40.3x | 2x |
| Tue, 16 Dec 2025 | SEK 32.6b | SEK 14.9b | -SEK 744,515,427.00 | 54.2x | -43.8x | 2.2x |
| Thu, 13 Nov 2025 | SEK 34.9b | SEK 14.9b | -SEK 736,298,012.00 | 58.4x | -47.5x | 2.4x |
| Sat, 11 Oct 2025 | SEK 34.6b | SEK 14.7b | SEK 61.3m | 51.5x | 564.4x | 2.4x |
| Mon, 08 Sep 2025 | SEK 34.9b | SEK 14.7b | SEK 60.9m | 56.4x | 573.3x | 2.4x |
| Wed, 06 Aug 2025 | SEK 35.7b | SEK 14.8b | SEK 158.0m | 60.9x | 226.1x | 2.4x |
| Fri, 04 Jul 2025 | SEK 47.1b | SEK 16.6b | SEK 416.3m | 71.6x | 113x | 2.8x |
| Sun, 01 Jun 2025 | SEK 45.8b | SEK 16.6b | SEK 404.2m | 72.2x | 113.2x | 2.8x |
| Tue, 29 Apr 2025 | SEK 43.9b | SEK 16.6b | SEK 642.3m | 44.2x | 68.4x | 2.6x |
| Thu, 27 Mar 2025 | SEK 35.9b | SEK 16.6b | SEK 614.3m | 38.8x | 58.4x | 2.2x |
| Sat, 22 Feb 2025 | SEK 41.8b | SEK 16.6b | SEK 615.4m | 41.4x | 67.9x | 2.5x |
| Mon, 20 Jan 2025 | SEK 39.1b | SEK 16.7b | -SEK 1,152,911,426.00 | 42.2x | -33.9x | 2.3x |
| Wed, 18 Dec 2024 | SEK 42.9b | SEK 16.7b | -SEK 1,152,911,426.00 | 48.6x | -37.2x | 2.6x |
| Fri, 15 Nov 2024 | SEK 43.1b | SEK 16.8b | -SEK 948,072,426.00 | 49.3x | -45.5x | 2.6x |
| Sun, 13 Oct 2024 | SEK 47.1b | SEK 16.7b | -SEK 988,175,491.00 | 58.4x | -47.7x | 2.8x |
| Tue, 10 Sep 2024 | SEK 48.8b | SEK 16.7b | -SEK 988,176,492.00 | 60.9x | -49.3x | 2.9x |
| Thu, 08 Aug 2024 | SEK 48.0b | SEK 16.7b | -SEK 1,128,120,510.00 | 60.6x | -42.6x | 2.9x |
| Sat, 06 Jul 2024 | SEK 43.8b | SEK 16.3b | -SEK 1,188,686,510.00 | 57x | -36.8x | 2.7x |
| Mon, 03 Jun 2024 | SEK 43.6b | SEK 16.3b | -SEK 1,188,686,510.00 | 62.9x | -36.7x | 2.7x |
| Wed, 01 May 2024 | SEK 38.5b | SEK 16.2b | -SEK 1,241,845,705.00 | 37.4x | -31x | 2.4x |
| Fri, 29 Mar 2024 | SEK 40.6b | SEK 16.0b | -SEK 1,122,792,210.00 | 35.6x | -36.2x | 2.5x |
| Sun, 25 Feb 2024 | SEK 38.7b | SEK 15.9b | -SEK 1,124,012,667.00 | 42.6x | -34.5x | 2.4x |
| Tue, 23 Jan 2024 | SEK 36.5b | SEK 15.5b | -SEK 1,393,723,683.00 | 44.3x | -26.2x | 2.4x |
| Thu, 21 Dec 2023 | SEK 37.4b | SEK 15.5b | -SEK 1,393,723,683.00 | 44.4x | -26.8x | 2.4x |
| Sat, 18 Nov 2023 | SEK 33.1b | SEK 15.4b | -SEK 1,398,076,683.00 | 35.5x | -23.6x | 2.1x |
| Mon, 16 Oct 2023 | SEK 24.0b | SEK 15.1b | -SEK 1,134,516,711.00 | 33.5x | -21.2x | 1.6x |
| Wed, 13 Sep 2023 | SEK 27.7b | SEK 15.1b | -SEK 1,133,713,072.00 | 38.8x | -24.5x | 1.8x |
| Fri, 11 Aug 2023 | SEK 32.4b | SEK 15.1b | -SEK 213,871,038.00 | 46.2x | -151.4x | 2.2x |
| Sun, 09 Jul 2023 | SEK 36.2b | SEK 14.6b | -SEK 172,476,038.00 | 39x | -209.8x | 2.5x |
| Tue, 06 Jun 2023 | SEK 39.9b | SEK 14.6b | -SEK 172,476,038.00 | 39.9x | -231.3x | 2.7x |
Price to Earnings Ratio
-231.3x
Current Industry PE
- Investors are pessimistic on the Swedish Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 2.4x is higher than the industry's current PS ratio of 2.0x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Swedish Clinical Research and Equipment compare with similar industries?
| SE Market | -0.18% | |
| Healthcare | -0.70% | |
| Life Sciences | -3.56% | |
| Clinical Research and Equipment | -3.56% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| PRO Promimic | SEK 14.40 | 28.6% +SEK 60.5m | -24.0% | PS5.5x | |
| IDLDX IDL Diagnostics | SEK 0.48 | 2.1% +SEK 2.3m | -18.6% | PS2x |